Finance

Lists
SANOFI80:BKK
SANOFI80 KTB DR
THB 2.94
0.00%
(0.00) 1D
Sep 4, 11:48:42 PM GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for SANOFI80...
Open
THB 2.94
High
THB 2.96
Low
THB 2.92
Mkt. cap
107.47B
Avg. vol.
78.51K
Volume
56.29K
52-wk high
THB 3.44
52-wk low
THB 2.70
Shares outstanding
1.21B
No. of employees
75K
Open
THB 2.94
High
THB 2.96
Low
THB 2.92
Mkt. cap
107.47B
Avg. vol.
78.51K
Volume
56.29K
52-wk high
THB 3.44
52-wk low
THB 2.70
Shares outstanding
1.21B
No. of employees
75K
Profile
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company trades as "SAN" on Euronext Paris and "SNY" on Nasdaq in the United States, and is a component of the Euro Stoxx 50 stock market index. In 2023, the company was ranked 89th in the Forbes Global 2000. Sanofi engages in the research and development, manufacturing, and marketing of pharmacological products, principally in the prescription market, but the firm also develops over-the-counter medications. The corporation covers seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. It is one of the world's largest producer of vaccines through its subsidiary Sanofi Pasteur. Wikipedia
About SANOFI80 KTB DR
CEOPaul Hudson | Belén Garijo
Employees74.8K
Founded1973
HeadquartersParis, ÃŽle-de-France, France
SectorPharmaceutical industry
Websitesanofi.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.17B
12.20B
11.24B
12.30B
Cost of goods sold
3.41B
3.63B
3.06B
2.89B
Cost of revenue
3.41B
3.63B
3.06B
2.89B
Research and development expenses
1.83B
2.29B
1.75B
2.23B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.29B
2.82B
2.33B
2.49B
Operating expense
5.97B
6.84B
5.94B
6.82B
Total operating expenses
9.39B
10.46B
9.00B
9.71B
Operating income
3.78B
1.74B
2.25B
2.59B
Other non operating income
-
122.00M
-40.00M
-91.00M
EBT including unusual items
3.51B
-1.16B
2.01B
828.00M
EBT excluding unusual items
3.67B
1.70B
2.14B
2.40B
Income tax expense
680.00M
-348.00M
420.00M
451.00M
Effective tax rate
19.38%
30.13%
20.85%
54.47%
Other operating expenses
1.39B
1.19B
1.33B
1.55B
Net income
2.80B
-801.00M
1.61B
343.00M
Net profit margin
21.28%
-6.56%
14.35%
2.79%
Earnings per share
-
1.53
1.88
-
Interest and investment income
114.00M
79.00M
60.00M
64.00M
Interest expense
-227.00M
-
-138.00M
-153.00M
Net interest expenses
-113.00M
79.00M
-78.00M
-89.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
4.20B
3.49B
2.78B
3.83B
Gain or loss from assets sale
266.00M
-79.00M
-
-9.00M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps